June 12, 2018 (GLOBENEWSWIRE)- Plandai Biotechnology, Inc., producer of the highly bioavailable Phytofare® catechin complex, today discussed the potential benefits of using highly-bioavailable green tea catechins, like those found in the Company’s proprietary Phytofare® extract, in treating people suffering from Type II diabetes. Worldwide as of 2013, 382 million people, or 8.3% of the adult population, have diabetes, with Type II Diabetes making up about 90% of the cases. In 2014, the International Diabetes Federation estimated that diabetes resulted in 4.9 million annual deaths.
Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, may exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and reductions in fat mass, triglycerides, free fatty acids and total cholesterol. The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins. Human studies have shown anti-obesity, anti-diabetic and cardio-protective properties of green tea catechins (1).
Callum Cottrell-Duffield, Chief Operating Officer of Plandai, commented, “Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets. There is a strong body of scientific research suggesting the effectiveness of green tea catechins in managing obesity, high blood pressure, Type II diabetes and other diet-related diseases. These prior studies, however, concur that green tea catechins are poorly absorbed into the blood stream, rendering them an ineffective primary control therapy. Phytofare®, on the other hand, which has ten-times greater absorption, may very well provide an inexpensive, all-natural solution to these diseases. We want to build on this prior research and show the benefits of Phytofare® in managing glucose levels, with a short-term goal of having a consumer-ready capsule product.”
(1) F. Thielecke, M. Boschmann / Phytochemistry (2009) “The potential role of green tea catechins in the prevention of the metabolic syndrome”
What are your thoughts about this?
